Histopathology

组织病理学

• 批准号: 7891957
• 负责人: William M Baldwin
• 金额: $ 24.72万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-08 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7891957
• 关键词: Animals; Antibodies; Computer software; Controlled Study; Cost Savings; Documentation; Experimental Designs; Frozen Sections; Histopathology; Image Analysis; Manuscripts; Methods; Microscopic; Paraffin Embedding; Pathology; Photography; Preparation; Process; Quality Control; Reagent; Research Personnel; Resources; Retrieval; Slide; Staining method; Stains; Tissue Stains; Tissues; digital; quality assurance; research study; tissue processing

The Histopathology Core will provide integral support for all 3 projects. This core will centralize the pathology resources for all of the projects of the PPG. This will result in cost savings, increased quality control and maximal comparability between the results of the projects. Key funcfions of the Core include: 1) expert advise in immunohistological aspects of experimental design to optimize results; 2) uniform tissue processing; 3) tissue secfioning (frozen sections and paraffin-embedded sections); 4) histochemical and immunohistochemical staining of tissue secfions; 5) pathological interpretation of fissue sections; 6) documentafion of the pathology by high quality digital microscopic photography; 7) preparation of figures for manuscripts; 8) storage and retrieval of stained slides for each of the projects. In addifion, this Core will be responsible for ordering, quality assurance and control studies of all anfibodies and reagents for use in the pathology methods. New reagents will be developed and evealuated as requested by investigators in the 3 projects.

组织病理学核心将为所有 3 个项目提供整体支持。该核心将集中 PPG 所有项目的病理资源。这将节省成本、提高质量 项目结果之间的控制和最大可比性。 核心的主要功能包括：1）在实验设计的免疫组织学方面提供专家建议 优化结果； 2）组织处理均匀； 3) 组织切片（冰冻切片和石蜡包埋） 部分）； 4) 组织切片的组织化学和免疫组织化学染色； 5）病理性的 组织切片的解释； 6) 通过高质量数字显微镜记录病理学 摄影; 7）稿件图表的准备； 8) 存储和检索每个的染色载玻片 项目。 此外，该核心将负责所有抗体的订购、质量保证和控制研究 以及用于病理学方法的试剂。新试剂将被开发和评估 应这 3 个项目的研究人员的要求。